Phibro Animal Health Corporation reports developments in animal health, mineral nutrition and performance products for food-animal markets. The company develops, manufactures and markets antibacterials, anticoccidials, nutritional specialty products, vaccines and mineral nutrition products for poultry, swine, beef and dairy cattle, and aquaculture in the United States and international markets.
Recurring PAHC news includes quarterly results and guidance, cash dividend declarations on Class A and Class B common stock, investor conference participation and regulatory updates affecting antimicrobial products such as virginiamycin and bacitracin. Company updates also address product portfolio activity, acquisition-related effects, input and distribution costs, foreign-currency impacts and tools such as PhibroVet for veterinary prescription management.
Phibro Animal Health (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend is payable on June 24, 2026 to shareholders of record at the close of business on June 3, 2026.
Phibro Animal Health (Nasdaq: PAHC) launched a companywide Sustainable Solutions Platform (SSP) and introduced Verratain Verified Sustainability Solutions, a master brand of low‑carbon microalgae feed ingredients. The initial Verratain line, via a strategic partnership with VAXA Technologies, includes Verratain Spirulina and Verratain Omega Oil and targets Scope 3 emissions in feed supply chains. Phibro appointed Peter Bunce as Head of Sustainable Solutions and expects initial sales within the coming months.
Phibro Animal Health (Nasdaq: PAHC) will announce third-quarter results on Wednesday, May 6, 2026 after the market close.
Management will host a conference call and webcast on Thursday, May 7, 2026 at 9:00 AM ET. Live audio and presentation slides will be available at https://investors.pahc.com; replay posted about two hours after the event.
Phibro Animal Health (Nasdaq: PAHC) announced a regulatory change in Brazil after MAPA published Ordinance No. 1617 on April 27, 2026. The ordinance prohibits importation, manufacture, marketing and use of certain growth-promotion antimicrobials, including virginiamycin and bacitracin, after a 180-day transition.
During the 180-day transition companies may continue current sales and labeling; afterward use will require a veterinary prescription. Phibro expects limited impact on fiscal 2026 and will provide more details on its May 7, 2026 earnings call.
Phibro Animal Health (Nasdaq: PAHC) will present at the Bank of America 2026 Virtual Animal Health Summit on Thursday, February 26, 2026 at 10:45 AM ET. Senior leaders including CFO Glenn David, COO Larry Miller and EVP/CEO designate Daniel Bendheim will address analysts and investors.
The live audio presentation and a replay will be available on the company's Investor Relations website and archived for later access.
Phibro Animal Health (Nasdaq: PAHC) reported strong Q2 results for the quarter ended December 31, 2025, with net sales $373.9M (+21%), net income $27.5M, adjusted EBITDA $68.1M (+41%) and raised fiscal 2026 guidance to $1.45B–$1.50B in net sales and $245M–$255M adjusted EBITDA.
Growth was driven by Animal Health, including MFA portfolio contributions, higher gross margin (35.5%), improved free cash flow ($47.3M LTM) and a 3.1x gross leverage ratio as of Dec 31, 2025.
Phibro Animal Health (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on both Class A and Class B common stock. The dividend was declared on Feb 3, 2026, is payable on Mar 25, 2026, to shareholders of record at close of business on Mar 4, 2026.
Phibro Animal Health (Nasdaq: PAHC) will release second quarter results on Wednesday, February 4, 2026 after market close and will host a conference call and webcast on Thursday, February 5, 2026 at 9:00 AM ET.
Investors can join live via the investor site, dial +1 (888) 330-2022 (U.S./Canada) or +1 (365) 977-0051 (international) using conference ID 3927884. A replay will be available about two hours after the live event on the investor website.
Phibro Animal Health (Nasdaq: PAHC) announced a planned leadership transition effective July 1, 2026. Jack Bendheim will move from CEO and President to Executive Chairman while remaining Board Chairman. Daniel (Dani) Bendheim will become Chief Executive Officer and President. Jack has led the company since 1969, served as President since 1988 and was CEO since March 2014. Dani joined in 1997 and has held roles including VP of Business Development, President of Performance Products, Executive VP Corporate Strategy and most recently Chief Transformation Officer overseeing the Phibro Forward initiative. The Board gave unanimous support and the full executive team will remain in place.
Phibro Animal Health (Nasdaq: PAHC) reported a strong start to fiscal 2026 for the quarter ended September 30, 2025, with net sales of $363.9M (up 40%) and net income $26.5M. Animal Health sales rose 55% to $283.5M driven by MFAs, nutritional specialties and vaccines. Adjusted EBITDA for the quarter was $61.9M and management raised FY2026 adjusted EBITDA guidance to $230M–$240M while maintaining net sales guidance of $1.43B–$1.48B. Balance sheet highlights include $749.1M total debt, 3.3x gross leverage and $85.3M cash and short-term investments.